Nectar Lifesciences is currently trading at Rs. 11.84, up by 0.21 points or 1.81% from its previous closing of Rs. 11.63 on the BSE.

The scrip opened at Rs. 11.25 and has touched a high and low of Rs. 11.98 and Rs. 11.21 respectively. So far 35116 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 29.95 on 07-Mar-2025 and a 52 week low of Rs. 11.21 on 04-Mar-2026.

Last one week high and low of the scrip stood at Rs. 12.50 and Rs. 11.21 respectively. The current market cap of the company is Rs. 224.76 crore.

The promoters holding in the company stood at 44.91%, while Institutions and Non-Institutions held 6.36% and 48.73% respectively.

Nectar Lifesciences has received approval to acquire 100% paid-up equity share capital of Avensis Exports (AEPL). The proposed acquisition of AEPL will help the company to enter into a real estate business. AEPL’s exposures in land and collaborations with other real estate companies will help the company to set its footprints in the real estate arena. This investment will allow the company to diversify, strengthen its position in the real estate business. The cost of the said acquisition is Rs 24.96 lakh and is expected to be completed within a period of 1 month. 

Post acquisition, AEPL will become a wholly owned subsidiary of the company. The board of directors of the company in its meeting held on March 02, 2026, has, inter-alia, approved the same.

Nectar Lifesciences, Incorporated in 1995, is a leading global manufacturer of cephalosporin antibiotics medicines.